GlassScriptPhysician profile
Diane Madfes
NPI 1942366547
$4,680.58
in general payments reported to CMS, 2019-2025
19 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $63.59 · 2021: $124 · 2022: $62.40 · 2023: $39.65 · 2024: $305 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,325 · Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,325.00 |
| Food and Beverage | $811.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,325.00 | 2025 | Spevigo |
| Galderma Laboratories, L.P. | $819.28 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Merz North America, INC. | $337.82 | 2019 | |
| Mimedx Group, INC. | $247.49 | 2025 | |
| Leo Pharma INC. | $137.09 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $131.08 | 2019-2025 | Clear & Brilliant, Fraxel |
| Amgen INC. | $123.72 | 2021 | |
| Revance Therapeutics, INC. | $91.17 | 2024 | Daxxify |
| Endo Pharmaceuticals INC. | $90.34 | 2019 | |
| Epi Health, LLC | $53.55 | 2019-2020 | |
| Abbvie INC. | $52.18 | 2019-2023 | |
| Incyte Corporation | $50.88 | 2025 | Opzelura |
| Celgene Corporation | $42.00 | 2019 | |
| Allergan, INC. | $40.45 | 2019-2020 | |
| Pfizer INC. | $39.17 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $36.18 | 2019-2025 | |
| Dermira, INC. | $27.66 | 2019-2020 | |
| Biofrontera INC. | $21.54 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Madfes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.